ArticleDrugs in context2025
Sustained disease control with pembrolizumab-lenvatinib in a patient with heavily pre-treated recurrent endometrial carcinoma: a case report.
Article in Drugs in context, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advancing endometrial cancer treatment: exploring immunotherapy and tyrosine kinase inhibitors through clinical cases.Drugs in context · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advanced endometrial carcinoma (EC) is typically associated with poor prognosis. However, recent advances have revolutionized therapeutic strategies. In patients with microsatellite stable (MSS) advanced EC, pembrolizumab plus lenvatinib have significantly improved overall survival, progression-free survival and response rate compared to standard chemotherapy. We describe the case of a 63-year-old woman with advanced endometrioid adenocarcinoma exhibiting mismatch repair proficiency (pMMR) and MSS who started treatment with pembrolizumab and lenvatinib after failing multiple lines of therapy. The patient had a favourable response, with mild side effects, and continues to receive treatment. Our experience supports pembrolizumab plus lenvatinib as a promising therapeutic option for patients with advanced recurrent EC with pMMR/MSS. This article is part of the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.